Integra LifeSciences (NASDAQ:IART) Trading Up 4.5% - Should You Buy?

Key Points

• Integra LifeSciences' stock price rose 4.5% during mid-day trading, reaching $14.69, despite a significant decline in trading volume compared to the average.
• Recent analyst reports have downgraded the company's stock price targets significantly, with ratings ranging from "Buy" to "Sell," leading to an average target price of $18.63.
• Integra LifeSciences reported earnings per share of $0.45 for the last quarter, exceeding estimates, but showed a revenue decline of 0.6% compared to the previous year.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s stock price was up 4.5% during mid-day trading on Tuesday . The company traded as high as $14.70 and last traded at $14.69. Approximately 544,413 shares changed hands during trading, a decline of 47% from the average daily volume of 1,024,711 shares. The stock had previously closed at $14.05.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IART. Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, JMP Securities reduced their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of "Reduce" and an average price target of $18.63.

Integra LifeSciences Stock Up 8.6%

The firm has a market cap of $1.16 billion, a P/E ratio of -2.28, a price-to-earnings-growth ratio of 0.84 and a beta of 1.16. The company has a fifty day simple moving average of $12.77 and a 200-day simple moving average of $16.39. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same quarter last year, the business posted $0.63 earnings per share. The firm's revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the stock. LPL Financial LLC bought a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $255,000. Raymond James Financial Inc. purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at approximately $943,000. First Trust Advisors LP boosted its holdings in shares of Integra LifeSciences by 319.7% in the fourth quarter. First Trust Advisors LP now owns 186,300 shares of the life sciences company's stock valued at $4,225,000 after purchasing an additional 141,907 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Integra LifeSciences by 5.3% in the fourth quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock valued at $947,000 after purchasing an additional 2,111 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Integra LifeSciences by 388.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,847 shares of the life sciences company's stock valued at $427,000 after purchasing an additional 14,985 shares during the period. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.